Healthcare provider profile · identity verified

Paul D Freel

Family Practice · GREENVILLE, SC · NPI 1528088721

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	381	127
Amlodipine Besylate	Amlodipine Besylate	277	103
Rosuvastatin Calcium	Rosuvastatin Calcium	258	83
Levothyroxine Sodium	Levothyroxine Sodium	255	77
Lisinopril	Lisinopril	220	80
Omeprazole	Omeprazole	212	73
Losartan Potassium	Losartan Potassium	199	65
Hydrochlorothiazide	Hydrochlorothiazide	171	62
Tamsulosin Hcl	Tamsulosin Hcl	164	61
Gabapentin	Gabapentin	163	50
Escitalopram Oxalate	Escitalopram Oxalate	142	47
Metformin Hcl Er	Metformin Hcl	137	48
Metoprolol Succinate	Metoprolol Succinate	133	50
Albuterol Sulfate Hfa	Albuterol Sulfate	120	40
Pantoprazole Sodium	Pantoprazole Sodium	112	39
Furosemide	Furosemide	104	38
Metformin Hcl	Metformin Hcl	100	33
Simvastatin	Simvastatin	100	32
Carvedilol	Carvedilol	88	28
Duloxetine Hcl	Duloxetine Hcl	83	25
Montelukast Sodium	Montelukast Sodium	83	28
Jardiance	Empagliflozin	78	23
Zolpidem Tartrate	Zolpidem Tartrate	76	12
Allopurinol	Allopurinol	73	24
Valsartan	Valsartan	71	27
Ozempic	Semaglutide	68	18
Mirtazapine	Mirtazapine	65	25
Eliquis	Apixaban	63	15
Clopidogrel	Clopidogrel Bisulfate	62	22
Lorazepam	Lorazepam	58	12
Pregabalin	Pregabalin	57	22
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	56	18
Irbesartan	Irbesartan	54	18
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	54	15
Pravastatin Sodium	Pravastatin Sodium	54	15
Famotidine	Famotidine	52	16
Trazodone Hcl	Trazodone Hcl	51	17
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	50	45
Fluticasone Propionate	Fluticasone Propionate	50	20
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	48	15
Doxycycline Hyclate	Doxycycline Hyclate	48	42
Finasteride	Finasteride	47	14
Meloxicam	Meloxicam	44	18
Synthroid	Levothyroxine Sodium	43	11
Potassium Chloride	Potassium Chloride	41	17
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	41	14
Atenolol	Atenolol	40	13
Ezetimibe	Ezetimibe	40	15
Tramadol Hcl	Tramadol Hcl	40	12
Celecoxib	Celecoxib	38	12
Sertraline Hcl	Sertraline Hcl	38	13
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	37	12
Triamcinolone Acetonide	Triamcinolone Acetonide	37	21
Alendronate Sodium	Alendronate Sodium	35	15
Temazepam	Temazepam	35	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	34	14
Tizanidine Hcl	Tizanidine Hcl	34	16
Ondansetron Odt	Ondansetron	32	18
Venlafaxine Hcl Er	Venlafaxine Hcl	32	suppressed
Benazepril Hcl	Benazepril Hcl	31	11
Esomeprazole Magnesium	Esomeprazole Magnesium	31	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	31	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	29	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	28	24
Fluoxetine Hcl	Fluoxetine Hcl	27	suppressed
Spironolactone	Spironolactone	27	13
Trulicity	Dulaglutide	27	suppressed
Buspirone Hcl	Buspirone Hcl	26	suppressed
Mounjaro	Tirzepatide	26	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	25	suppressed
Fluconazole	Fluconazole	25	14
Glimepiride	Glimepiride	25	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	24	suppressed
Nystatin	Nystatin	24	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	24	suppressed
Clonazepam	Clonazepam	23	suppressed
Prednisone	Prednisone	23	suppressed
Cefdinir	Cefdinir	22	16
Estradiol	Estradiol	22	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	22	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	22	suppressed
Novolog Flexpen	Insulin Aspart	22	suppressed
Xarelto	Rivaroxaban	22	suppressed
Donepezil Hcl	Donepezil Hcl	21	suppressed
Farxiga	Dapagliflozin Propanediol	20	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	20	suppressed
Methylprednisolone	Methylprednisolone	19	19
Januvia	Sitagliptin Phosphate	18	suppressed
Breo Ellipta	Fluticasone/Vilanterol	17	suppressed
Clonidine Hcl	Clonidine Hcl	17	suppressed
Diclofenac Sodium	Diclofenac Sodium	17	suppressed
Nitroglycerin	Nitroglycerin	17	13
Ondansetron Hcl	Ondansetron Hcl	17	suppressed
Chlorthalidone	Chlorthalidone	16	suppressed
Eszopiclone	Eszopiclone	16	suppressed
Fenofibrate	Fenofibrate	16	suppressed
Repaglinide	Repaglinide	16	suppressed
Rybelsus	Semaglutide	16	suppressed
Testosterone Cypionate	Testosterone Cypionate	16	suppressed
Tresiba Flextouch U-100	Insulin Degludec	16	suppressed
Clorazepate Dipotassium	Clorazepate Dipotassium	15	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	15	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	15	suppressed
Indapamide	Indapamide	15	suppressed
Symbicort	Budesonide/Formoterol Fumarate	15	11
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	15	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	15	suppressed
Colchicine	Colchicine	14	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Alprazolam	Alprazolam	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Torsemide	Torsemide	13	suppressed
Dexlansoprazole Dr	Dexlansoprazole	12	suppressed
Humalog Kwikpen U-100	Insulin Lispro	12	suppressed
Bupropion Xl	Bupropion Hcl	11	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	11	suppressed
Nexletol	Bempedoic Acid	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Sucralfate	Sucralfate	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error